PDCD1 and neoplasm: In addition, a shorter progression-free survival (PFS) could be observed for patients with >3 PD-1+ CTCs at baseline (p = 0.022) but not for PD-L1 expressing tumor cells, thus suggesting a potential clinical role for PD-1+ CTCs rather than for PD-L1+ CTCs [25].